Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730964 · ClinicalTrials.gov registry record · Phase 4
A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
A Phase 4 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,039
- Enrollment target
NCT00730964: Completed Phase 4 study, sponsored by GE Healthcare.
NCT00730964 is a Phase 4 study that has completed, run by GE Healthcare. The registered enrollment target is 1,039 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (101% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00730964, a Phase 4 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,039 participants
- Enrollment target
Study Summary
This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.
Primary Outcome
A Serious Adverse Reaction or (SAR) is considered causally related to the Optison product administered by the investigator. This reaction, should it occur, will be counted as a serious adverse reaction.
Interventions
- DRUG Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,039 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
What the finished NCT00730964 record still lists
NCT00730964 is an interventional study that assigns participants to a tested intervention. Its 1,039 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (101% higher).
The record links to 0 conditions, and to 1 intervention - of which Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP) is the first listed.
NCT00730964 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00730964 about?
NCT00730964 is a clinical study titled "A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.". This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.
What is the current status of trial NCT00730964?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,039 participants. The study started on 2008-05. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00730964?
The interventions under investigation include: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP) (DRUG).
Who is sponsoring clinical trial NCT00730964?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00730964's enrollment target sits among peer trials
1,039 66th of 2000 higher than 1,935 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
- NCT06661720 · 1,040 participants · Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- NCT07345767 · 1,038 participants · NA
Hypknowledge Nationwide Sleep Extension
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia